Product Description
ASP2409 represents a new class of CTLA4-Ig molecules with higher binding avidity and selectivity to CD86.
Mechanisms of Action: Immunosuppressive
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2409-CL-0104 | P1 |
Completed |
Arthritis, Rheumatoid |
2014-04-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|